Humanin
$Mitochondrial-derived cytoprotective peptide; Strong preclinical signal, limited human intervention data
Humanin is a small peptide made from a short open reading frame inside the mitochondrial 16S rRNA region. It is best understood as a cellular stress-response and survival signal, not as an approved anti-aging injection.
Humanin has a serious scientific literature, especially in neuroprotection, metabolism, cardiovascular stress, and aging biology. The weak point is translation: most therapeutic claims come from cell, animal, or biomarker studies. Human clinical supplementation trials are not established. Separate native humanin from modified analogs such as S14G-humanin (HNG) and HNGF6A.
These analogs may be more potent or have different binding and pharmacokinetic behavior. A paper on HNG is not automatically proof for an unmodified gray-market Humanin vial.
Classification details
- Humanin is a mitochondrial-derived peptide encoded within the MT-RNR2 region, the gene region that also encodes mitochondrial 16S rRNA.
- The commonly listed 24-amino-acid human sequence is MAPRGFSCLLLLTSEIDLPVKRRA.
- Some sources distinguish a 21-amino-acid mitochondrial-translated form from a 24-amino-acid cytosolic form, and both have been discussed as biologically active.
- Chemically, PubChem lists Humanin with formula C119H204N34O32S2 and molecular weight about 2687.2 g/mol.
- That makes it substantially larger than ultrashort bioregulators such as Vilon, but much smaller than protein hormones.
- In this guide it belongs with mitochondrial-derived peptides and cytoprotective research peptides, adjacent to MOTS-c but mechanistically distinct.
- A common mistake is to treat Humanin, MOTS-c, SHLP2, and NAD+ as interchangeable mitochondrial products. They are not.
- Humanin is mainly discussed as an anti-apoptotic and stress-resistance signal. MOTS-c is more often discussed around metabolic signaling and exercise adaptation. NAD+ is not a peptide at all.
- Humanin is a mitochondrial-derived peptide family concept, not a conventional hormone replacement. Analogs and native humanin are distinct, because potency and stability can differ.
- Humanin is usually described as cytoprotective and anti-apoptotic.
- Proposed intracellular actions include binding or interfering with pro-apoptotic proteins such as Bax, Bid/tBid, and BimEL, thereby reducing stress-triggered cell death. This is one reason the peptide appears often in neurodegeneration and ischemia-reperfusion discussions.
- Humanin also has extracellular signaling models. Reviews describe interaction with a receptor complex involving CNTF receptor alpha, WSX-1, and gp130, and also interaction with formyl peptide receptor-like receptors such as FPRL1/FPR2.
- These pathways connect Humanin to STAT3, ERK, and AKT signaling, inflammatory tone, oxidative stress handling, and cellular survival responses.
- The IGF axis matters. Humanin and analogs can associate with IGF-binding proteins, especially IGFBP-3, which may influence circulating duration and tissue exposure. That makes simplistic claims like “Humanin just repairs mitochondria” inaccurate.
- Its biology is broader: apoptosis control, stress signaling, inflammatory modulation, endocrine cross-talk, and mitochondrial function all overlap.
- Mechanisms involve cytoprotection, mitochondrial stress signaling, apoptosis modulation, insulin sensitivity, and neuroprotection hypotheses. These are broad stress-response pathways, not one validated clinical endpoint.